Literature DB >> 9705366

Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain.

J A Pineda1, J A Gallardo, J Macías, J Delgado, C Regordán, F Morillas, F Relimpio, J Martín-Sánchez, A Sánchez-Quijano, M Leal, E Lissen.   

Abstract

The actual prevalence of visceral leishmaniasis among human immunodeficiency type 1 (HIV-1)-infected patients in the Mediterranean basin remains unknown. There is also controversy about the risk factors for Leishmania infantum and HIV-1 coinfection. To appraise the prevalence of visceral leishmaniasis in patients infected with HIV-1 in southern Spain and to identify factors associated with this disease, 291 HIV-1 carriers underwent a bone marrow aspiration, regardless of their symptoms. Giemsa-stained samples were searched for Leishmania amastigotes. Thirty-two (11%) patients showed visceral leishmaniasis. Thirteen (41%) patients had subclinical cases of infection. Centers for Disease Control and Prevention (CDC) clinical category C was the factor most strongly associated with this disease (adjusted odds ratio [OR], 1.88 [95% confidence interval, 1.22 to 2.88]), but patients with subclinical cases of infection were found in all CDC categories. Female sex was negatively associated with visceral leishmaniasis (adjusted OR, 0.42 [95% confidence interval, 0.18 to 0.97]). Intravenous drug users showed a higher prevalence than the remaining patients (13.3 versus 4.9%; P = 0.04), but such an association was not independent. These results show that visceral leishmaniasis is a very prevalent disease among HIV-1-infected patients in southern Spain, with a high proportion of cases being subclinical. Like other opportunistic infections, subclinical visceral leishmaniasis can be found at any stage of HIV-1 infection, but symptomatic cases of infection appear mainly when a deep immunosuppression is present. There is also an association of this disease with male sex and intravenous drug use.

Entities:  

Mesh:

Year:  1998        PMID: 9705366      PMCID: PMC105136     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Frequency of subclinical visceral leishmaniasis in HIV-1-infected patients in Spain.

Authors:  J A Pineda; J Hernández-Quero; J A Gallardo; M A López-Ruz; M A Martínez-Pérez; J Macías; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

Review 2.  AIDS and Leishmania infantum. New approaches for a new epidemiological problem.

Authors:  J Alvar; B Gutiérrez-Solar; I Pachón; E Calbacho; M Ramírez; R Vallés; J L Guillén; C Cañavate; C Amela
Journal:  Clin Dermatol       Date:  1996 Sep-Oct       Impact factor: 3.541

3.  Specificity of a commercial indirect immunofluorescence technique in the diagnosis of visceral leishmaniasis in patients infected with HIV-1.

Authors:  J A Gallardo; J A Pineda; J Macías; R Torronteras; E Lissen
Journal:  Trans R Soc Trop Med Hyg       Date:  1996 Jul-Aug       Impact factor: 2.184

4.  Prolonged Th2 cell activation and increased viral replication in HIV-Leishmania co-infected patients despite treatment.

Authors:  B Cacopardo; L Nigro; W Preiser; A Famá; M I Satariano; J Braner; B M Celesia; B Weber; R Russo; H W Doerr
Journal:  Trans R Soc Trop Med Hyg       Date:  1996 Jul-Aug       Impact factor: 2.184

Review 5.  Kala-azar comes to New York.

Authors:  V Parkas; J Godwin; H W Murray
Journal:  Arch Intern Med       Date:  1997-04-28

Review 6.  Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani.

Authors:  H Albrecht; I Sobottka; C Emminger; H Jablonowski; G Just; A Stoehr; T Kubin; B Salzberger; T Lutz; J van Lunzen
Journal:  Arch Pathol Lab Med       Date:  1996-02       Impact factor: 5.534

7.  Low sensitivity of peripheral blood smear for diagnosis of subclinical visceral leishmaniasis in human immunodeficiency virus type 1-infected patients.

Authors:  J Delgado; J A Pineda; J Macías; C Regordán; J A Gallardo; M Leal; A Sanchez-Quijano; E Lissen
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

8.  Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy.

Authors:  L Gradoni; A Scalone; M Gramiccia; M Troiani
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

9.  Injecting drug use as risk factor for visceral leishmaniasis in AIDS patients.

Authors:  C Amela; D López-Gay; J C Alberdi; J Castilla
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

Review 10.  [Leishmaniasis and human immunodeficiency virus infections].

Authors:  J P Dedet; M Lambert; F Pratlong
Journal:  Presse Med       Date:  1995-06-17       Impact factor: 1.228

View more
  14 in total

1.  Leishmaniasis at the End of the Millennium.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.725

2.  Opsonization modulates Rac-1 activation during cell entry by Leishmania amazonensis.

Authors:  J Morehead; I Coppens; N W Andrews
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

3.  Noninvasive method for diagnosis of visceral leishmaniasis by a latex agglutination test for detection of antigens in urine samples.

Authors:  C Vilaplana; S Blanco; J Domínguez; M Giménez; V Ausina; Cristina TUral; Carme Muñoz
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

4.  Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy.

Authors:  Rafael de La Rosa; Juan A Pineda; Juan Delgado; Juan Macías; Francisco Morillas; José A Mira; Armando Sánchez-Quijano; Manuel Leal; Eduardo Lissen
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

5.  Optimized PCR using patient blood samples for diagnosis and follow-up of visceral Leishmaniasis, with special reference to AIDS patients.

Authors:  L Lachaud; J Dereure; E Chabbert; J Reynes; J M Mauboussin; E Oziol; J P Dedet; P Bastien
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

6.  Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients.

Authors:  José A García-García; Joaquina Martín-Sánchez; Montserrat Gállego; Antonio Rivero-Román; Angela Camacho; Cristina Riera; Francisco Morillas-Márquez; Salvador Vergara; Juan Macías; Juan A Pineda
Journal:  J Clin Microbiol       Date:  2006-10-18       Impact factor: 5.948

7.  Visceral leishmaniasis in Malta--an 18 year paediatric, population based study.

Authors:  V Grech; J Mizzi; M Mangion; C Vella
Journal:  Arch Dis Child       Date:  2000-05       Impact factor: 3.791

Review 8.  Importance of nonenteric protozoan infections in immunocompromised people.

Authors:  J L N Barratt; J Harkness; D Marriott; J T Ellis; D Stark
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

9.  Unusual duodenal presentation of leishmaniasis.

Authors:  M L Alvarez-Nebreda; E Alvarez-Fernández; S Rada; F Brañas; E Marañón; M T Vidán; J A Serra-Rexach
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

10.  Leishmaniases in Northern Greece: seroprevalence of the infection and incidence of the disease during the period 2001-2006.

Authors:  E Diza; A Kansouzidou; S Gerou; E Vezyri; S Metallidis; A Antoniadis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-30       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.